Evidence map›Paper›PMID 42213826›Full record

ArticleScience advances2026

DHX36 is a regulatory switch in the interferon-mediated antiviral response.

Lisa Weixler, Daniel Hilbig, Philipp S Simon, Stefan Juranek, Julia Mahlberg, Martin Schlee, Eva Bartok, Markus Hafner, Katrin Paeschke

Abstract read
In one paragraph

Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lisa WeixlerInstitute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, 53127 Bonn, Germany.ORCID 0000-0003-4453-017X
Daniel HilbigDepartment of Oncology, Hematology, Rheumatology and Immune-Oncology, University Hospital Bonn, 53127 Bonn, Germany.
Philipp S SimonInstitute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, 53127 Bonn, Germany.ORCID 0009-0001-8144-0010
Stefan JuranekInstitute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, 53127 Bonn, Germany.ORCID 0000-0002-9136-4461
Julia MahlbergInstitute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, 53127 Bonn, Germany.ORCID 0000-0001-8103-8040
Martin SchleeInstitute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, 53127 Bonn, Germany.ORCID 0000-0003-3671-7639
Eva BartokInstitute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, 53127 Bonn, Germany.ORCID 0000-0003-0556-1950
Markus HafnerRNA Molecular Biology Laboratory, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD 20892, USA.ORCID 0000-0002-4336-6518
Katrin PaeschkeInstitute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, 53127 Bonn, Germany.ORCID 0000-0003-3080-6745

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Innate immune and stress responses must be tightly regulated to prevent aberrant activation in the absence of pathogens. The RNA helicase DHX36 has been implicated in viral RNA sensing, but its role in immune regulation is not fully understood. Here, we show that DHX36 functions as a rheostat that restrains immune activation under homeostatic conditions while modulating antiviral signaling. Exposure to double-stranded RNA reduces DHX36 activity, enabling immune activation. In contrast, cells lacking DHX36 adopt a constitutively activated immune state characterized by accumulation of RNA G-quadruplex structures, protein kinase R (PKR)-dependent stress granule formation, and elevated interferon-stimulated gene expression. These cells also display enhanced responsiveness to the viral RNA sensor retinoic acid-inducible gene I (RIG-I) and more effectively suppress replication of a yellow fever virus replicon. Together, our findings position DHX36 as a key regulator of the type I interferon response, linking RNA structure surveillance to coordinated PKR- and RIG-I-dependent antiviral signaling and maintenance of immune homeostasis.

Indexed as

DEAD-box RNA HelicasesImmunity, InnateInterferonsVirus DiseasesYellow fever virusClustered Regularly Interspaced Short Palindromic RepeatsDEAD Box Protein 58eIF-2 KinaseFlavivirus InfectionsGene EditingHEK293 CellsHumansNF-kappa BPoly I-CReceptors, ImmunologicSignal TransductionDEAD Box Protein 58DEAD-box RNA HelicasesDHX36 protein, humanEIF2AK2 protein, humaneIF-2 KinaseInterferonsNF-kappa BPoly I-CReceptors, ImmunologicRIGI protein, human

Identifiers

PMID42213826
PMCPMC13220864

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.